the cumulative responses revealed a relapsing and remitting course in 45.9%. Outcome predictors in univariate analysis were Jo-1 status, presence of arthritis, interstitial lung disease and pericardial effusion at baseline. On multivariate analysis, absence of pericardial effusion (p=0.011) and interstitial lung disease (p=0.067) at baseline were found to be predictors of complete response. Disease free survival probability estimated at 5 years and 10 years was 91.6% and 72.4% respectively. Estimating the probability gender wise, males achieved disease free status earlier than females.

Conclusion: A favorable clinical and functional outcome was seen in a significant proportion of these patients with IIM on long term follow up. Pericardial effusion and ILD were identified as predictors of poor clinical outcome.

References:

Acknowledgments: Nil

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5049

AB0597 PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: A NEW TOOL FOR SYSTEMIC SCLEROSIS CLASSIFICATION?

F. M. Ortiz Sanjuán1, C. Pávez Perales1, E. Vicens Bernabeu1, C. Alcañiz Escandell1, I. Cánovas Olmos1, I. Chalmeta Verdejo1, M. De la Rubia Navarro1, R. Gonzalez Mazarío1, L. González Puig1, E. Grau García1, J. Ivorra Cortés1, S. Leal Rodriguez1, I. Martínez Cordel1a, C. Nájera Herran1, R. Negueroles Albuixech1, J. E. Oller Rodríguez1, J. A. Román Ivorra1, E. Trespalacios1, L. Ibáñez2, J. Ivorra Cortés1, S. Leal Rodriguez1, I. Martínez Cordell1, C. Nájera Herrana1, R. Negueroles Albuixech1, J. E. Oller Rodríguez1, J. A. Román Ivorra1, E. Trespalacios1, L. Ibáñez2.

1. Rheumatology Department. HUP La Fe, Valencia, Spain

Background: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) and is often progressive and has a poor prognosis. A restrictive ventilatory defect could suggest ILD either alone or in combination with pulmonary arterial hypertension.

Nowadays, Early-SSc is well defined as preliminary stage of SSc. Patients who meet criteria for Early-SSc could benefit from an early diagnosis of pulmonary involvement.

Objectives: Our aim was to assess the pulmonary function in patients diagnosed of Early SSC.

Methods: Retrospective observational study of a wide and unselected series of patients diagnosed as Early-SSc from a single university hospital from 2012 to 2019. Patients were classified as Early-SSc following Le Roy criteria. Despite this, patients already did not meet 2013 ACR/EULAR classification criteria for SSC.

We reviewed pulmonary function through conventional spirometry and diffusing capacity of lung for carbon monoxide (DLCO).

Results: We included 56 patients with a mean age of 52.3±12.1 years (96.4% women; 3.6% men).

At the diagnosis of Early-SSc, no one of our patients exhibited a restrictive ventilatory pattern. DLCO was below normal limits in 18 patients (32.1%). Small airway obstruction expressed according decreased maximal (mid-) expiratory flow (MMEF) 25-75 was present in 24 patients (42.8%).

After a mean follow-up period of 38.3±2.4 months, 29 (51.8%) patients fulfilled 2013 ACR/EULAR criteria. The average time between diagnosis of Early-SSc and achieve SSc classification was 24.4±1.8 months. The remaining 27 patients continued classified as Early-SSc.

An analysis of the subgroup of patients which progressed to SSc showed that DLCO was decreased in 15 of those 29 patients (51.7%) and 18 of 29 patients (62.1%) presented decreased MMEF 25-75. Comparing with the subgroup of patients which not progressed to SSc were significant differences (Decreased DLCO: 51.7% vs 11.1%; p=0.02 and decreased MMEF 25-75: 42.8% vs 22.2%; p=0.05).

The analysis of pulmonary function of the subgroup of patients continued classified as Early-SSc after follow-up period did not show significant changes after follow-up.

Conclusion: In our study, a third of the patients classified as Early-SSc presented at diagnosis abnormal values of DLCO and/or signs of small airway obstruction without the presence of a restrictive ventilatory pattern. Moreover, this pulmonary dysfunction was significantly more frequent in patients who progressed to definitive SSc. Patients which remains classified as Early-SSc did not experience significant changes.

Our results support the concept that pulmonary function was impaired in Early-SSc and that I should probably be considered for future Early-SSc classification criteria.
AB0599 TREATMENT OF REFRACTORY DERMATOMYOSITIS WITH TOFACITINIB

K. Riggle1, A. Patel2, R. Aggarwal3, 1University of Virginia, Charlottesville, United States of America; 2University of Virginia, Charlottesville, United States of America; 3University of Pittsburgh, Pittsburgh, United States of America

Background: Dermatomyositis (DM) is a systemic, autoimmune disease affecting the skin and proximal skeletal muscles. A subset of DM patients present with subclinical or resolved muscle involvement but continue to have skin disease. In these cases, first and second line treatments including glucocorticoids are sometimes insufficient for controlling the disease, necessitating escalation of treatment. Several recent studies have investigated the response of Tofacitinib, an oral Janus Kinase inhibitor approved for the treatment of rheumatoid arthritis, in DM patients and patients with inflammatory skin diseases.

Objectives: Due to the reported ability of JAK inhibitors to suppress type 1 interferon (IFN) signaling, which is suspected to be upregulated in DM, we evaluated the efficacy of treatment with Tofacitinib in four refractory DM patients.

Methods: Four patients with dermatomyositis without evidence of current muscle involvement began treatment with Tofacitinib 11 mg daily after they had failed or had adverse effects to first and second line immunosuppressive agents. Their medical records were reviewed at 0, 3, and 6 months, with improvement measured using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score. Throughout their treatment they were additionally monitored for improvement in markers of inflammation and the necessity for concomitant treatments. Patients were monitored for adverse effects to Tofacitinib treatment.

Results: All four patients within the case series showed significant improvement of their cutaneous disease activity (CDASI scores improved by 8-15 points) over the first 6 months, with three of these having achieved minimal clinically improved difference of ≥5 points by three months. Based on the CDASI, three of the cases’ disease classification changed from moderate-to-severe disease to mild disease. The last patient initially presented with mild disease. Other outcomes noted included improved pruritus in 3 patients and improvement of calcinosis in 1 patient. One patient was additionally able to stop concomitant treatments. Patients were monitored for adverse effects to Tofacitinib treatment.

Conclusion: Tofacitinib is believed to play a role in the inhibition of IFN signaling pathways that are overactive in dermatomyositis. All four patients within this retrospective study showed significant improvement of cutaneous disease with Tofacitinib use.

References:

Disclosure of Interests: Kirsten Riggle: None declared, Aarav Patel Speakers bureau: Abbvie, Mallinckrodt, Celgene, Lilly, Rohit Aggarwal Grant/research support from: Pfizer, Genentech, BMS, Mallinckrodt, Consultant of: Pfizer, Genentech, BMS, Mallinckrodt, Bristol Myers-Squibb, octapharma, CSL Behring, AstraZeneca, Corbus, Kezar, Abbvie DOI: 10.1136/annrheumdis-2020-eular.1634

AB0600 THE EFFECTS OF HYPERBARIC OXYGEN THERAPY TO QUALITY OF LIFE AND STATE OF MICROCIRCULATION IN PATIENTS WITH SYSTEMIC SCLEROSIS - A PILOT STUDY

S. Pavlov-Dolianjovic1, V. Koletic2, N. Vujasinovic Stupar2, N. Damjanov2.
1Institute of Rheumatology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 2Centre for Hyperbaric Medicine, Belgrade, Serbia

Background: Many treatments have been tried in therapy systemic sclerosis (SSc) patients but use of hyperbaric oxygen therapy (HBOT) is very limited.

Objectives: To assess the effects of HBOT to quality of life and state of microcirculation in SSc patients.

Methods: 18 female patients aged 29-68 years (mean 57 years) with limited SSc and digital or leg ulcers were included in this work. The HBOT protocol comprised 20 sessions 5 days/week, 60 min, 100% oxygen at 2.2 ATA. The treated patients were evaluated at baseline and after 20 HBOT sessions. Evaluation consisted of physical examination, capillaroscopy, pulmonary function tests, biochemical analyses, socio-demographic and clinimetric questionnaires: Ssc Systemic Sclerosis Questionnaire (SySSQ) and Health Assessment Disability index Questionnaire (HAQ-DI).

Results: Mean value [before, after, mean (range)] for SySSQ [15.5 (4-48) vs 9.9 (3-31)], HAQ-DI [0.60 (0.28-88) vs 0.35 (0.175)], erythrocyte sedimentation rate [21 (4-42) vs 12 (3-27)], forced vital capacity [96.61±14.44% vs 115.94±16.69%], diffusing lung capacity of carbon monoxide [73.61±6.63% vs 87.33±9.30%] significantly improved after HBOT sessions (p=0.035), mean number of enlarged capillaries [21 vs 27, p=0.182], giant capillaries [14 vs 14, p=0.235] and ramified/bushy capillaries [14 vs 13, p=0.178] before and after HBOT. All patients had digital ulcers, and 5 patients had bilateral lesions (digital and leg ulcers). Mean size of ulceration before HBOT was 12±11mm, and after therapy was 4±4mm (p<0.001). Three patients had digital gangrene. Amputation was not necessary in any.

Conclusion: Our data confirm the efficacy of HBOT in treating SSc patients.

Further studies are required to evaluate the protocol and to understand the duration of the clinical effect.

References:

Disclosure of Interests: Stavica Pavlov-Dolianjovic: None declared, Vesna Koletic: None declared, Nada Vujasinovic Stupar: None declared, Nemanja Damjanov Grant/research support from: AbbVie, Pfizer, and Roche, Consultant of: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Speakers bureau: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche

DOI: 10.1136/annrheumdis-2020-eular.2610